Yang S, Wang H, Liu Y, et al. Clinical Pathway Management for Platelet-Rich Plasma Therapy in Kellgren-Lawrence Grade I and II Knee Osteoarthritis. Am J Sports Med, 2026

PMID 42929654

Double-blind RCT at 3 hospitals in China, 240 patients with KL I-II knee OA: standardised PRP pathway vs physician-directed PRP care. At 12 months VAS MD -2.98 (95% CI -3.64 to -2.32), WOMAC -8.63, IKDC +10.25; adverse events 14.8% vs 31.9%. No placebo; does not establish PRP efficacy.